- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01439295
Ascorbyl Peroxide Association With Bronchopulmonary Dysplasia
November 17, 2015 updated by: Ibrahim Mohamed, St. Justine's Hospital
Urinary Ascorbyl Peroxide as an Early Biological Marker of Bronchopulmonary Dysplasia in Preterm Infants Less Than 33 Weeks of Gestation
Urinary ascorbyl peroxide level in the first week of life will be a good predictor of Bronchopulmonary dysplasia (BPD) in preterm infants less than 33 weeks of gestation.
Study Overview
Status
Completed
Conditions
Detailed Description
This study uses ascorbyl peroxide as representative of oxidative stress in premature infants on parenteral nutrition and aims to test the correlation of this metabolite and the different major neonatal outcomes 'mainly bronchopulmonary dysplasia).
Study Type
Observational
Enrollment (Actual)
51
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3T1C5
- University of Montreal, Sainte-Justine Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 months to 7 months (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Preterm infants less than 33 weeks of getation
Description
Inclusion Criteria:
- Preterm infants less than 33 weeks of gestation<
- Admission to CHU Sainte-JUstien neonatal intensive care unit
- Receiving Parenteral nutrition during the first week of life
- Parental consent
Exclusion Criteria:
- Major congenital anomalies
- Sever perinatal asphyxia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Preterm less than 33 weeks
This cohort will be composed of premature infants born before 33 weeks of gestational age, admitted to the neonatal intensive care unit at Sainte-Justine hospital and receiving parenteral nutrition (PN) during their first week of life.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bronchopulmonary Dysplasia
Time Frame: 4 Months
|
To correlate the level of urinary Ascorbyl peroxide and BPD.
Full diagnosis and classification (to mild, moderate or severe) is at 36 weeks of corrected age; so even for most premature infants (like 23 weeks of gestation) there will be a need for follow up for less than 4 month to have the final diagnosis at 36 weeks
|
4 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The redox status (in blood)
Time Frame: First week of life (week 1) and 36 semaines CA
|
Testing the correlation between the urinary level of ascorbyl peroxide and the redox status in the blood at 5 to 7 days of life.
Measuring the Redox potential at 36 weeks corrected age to investigate long term effect of early oxidative stress.
|
First week of life (week 1) and 36 semaines CA
|
Major neonatal outcomes (NEC, ROP, PDA, IVH, PVL)
Time Frame: 4 Months
|
These outcomes are the major neonatal outcomes for preterm infants, we would test the correlation between ascorbyl peroxide (as marker of oxidative stress) and like Necrotising enterocolotis (NEC), Retinopathy of prematurity (ROP),patent ductus arteriosis(PDA), intraventricular hemorrhage (IVH) and periventricular leucomalacia (PVL).
|
4 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Ibrahim Mohamed, Mb CHB, University of Montreal, Sainte Justine Hospital
- Study Director: Jean-claude Lavoie, PhD, University of Montreal, Sainte-Justine hospital research center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
- Light-Induced Byproducts of Vitamin C in Multivitamin Solutions
- Association between Hydrogen Peroxide-Dependent Byproducts of Ascorbic Acid and Increased Hepatic Acetyl-CoA Carboxylase Activity
- Neonatal Exposure to Oxidants Induces Later in Life a Metabolic Response Associated to a Phenotype of Energy Deficiency in an Animal Model of Total Parenteral Nutrition
- Admixture of a Multivitamin Preparation to Parenteral Nutrition: The Major Contributor to In Vitro Generation of Peroxides
- Paradoxical Role of Ascorbic Acid and Riboflavin in Solutions of Total Parenteral Nutrition: Implication in Photoinduced Peroxide Generation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2010
Primary Completion (Actual)
November 1, 2015
Study Completion (Actual)
November 1, 2015
Study Registration Dates
First Submitted
September 16, 2011
First Submitted That Met QC Criteria
September 22, 2011
First Posted (Estimate)
September 23, 2011
Study Record Updates
Last Update Posted (Estimate)
November 18, 2015
Last Update Submitted That Met QC Criteria
November 17, 2015
Last Verified
November 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- University of Montreal
- CIHR246505 (Other Grant/Funding Number: Canadain Institute of Health Research (CIHR))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchopulmonary Dysplasia
-
Centre Hospitalier Intercommunal CreteilNot yet recruitingControls Born at Term | Premature With Dysplasia Bronchopulmonary | Premature Without Dysplasia Bronchopulmonary
-
Adel MohamedHealth Sciences Centre, Winnipeg, Manitoba; Mount Sinai Hospital, CanadaCompletedBronchopulmonary Dysplasia (BPD)Canada
-
Children's Hospital of PhiladelphiaCompleted
-
Cynthia McEvoyUniversity of Florida; University of California, San Francisco; Thrasher Research... and other collaboratorsCompletedBronchopulmonary Dysplasia (BPD)United States
-
Children's Hospital of Eastern OntarioThe Hospital for Sick Children; Hannover Medical School; MOUNT SINAI HOSPITAL; St... and other collaboratorsRecruitingLung Function | BPD - Bronchopulmonary DysplasiaCanada
-
Christoph HornikNational Heart, Lung, and Blood Institute (NHLBI); University of North Carolina...RecruitingBronchopulmonary Dysplasia of NewbornUnited States
-
Medipost Co Ltd.RecruitingSevere Bronchopulmonary DysplasiaKorea, Republic of
-
PediatrixPhoenix Children's Hospital; Banner HealthActive, not recruitingBPD - Bronchopulmonary DysplasiaUnited States
-
University of FloridaCompletedPreterm Infant | Barotrauma | BPD - Bronchopulmonary DysplasiaUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedBronchopulmonary Dysplasia; Retinopathy of PrematurityItaly